Trial Profile
The Effect of Live Attenuated Influenza Vaccine (LAIV) on Experimental Human Pneumococcal Colonisation (EHPC) Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs MEDI 3250 (Primary) ; GSK 2321138A
- Indications Influenza virus infections
- Focus Therapeutic Use
- Acronyms LAIV/EHPC
- 04 Sep 2017 Status changed from active, no longer recruiting to completed.
- 01 May 2017 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2015 Accrual to date is 47% according to United Kingdom Clinical Research Network.